

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (Presently amended): A method of screening for neuroprotective drugs compounds comprising the steps of

- a) obtaining a sample of free Postsynaptic density-95 protein having a free PDZ domain;
- b) taking a first NMR spectrum of the free PDZ domain of said free Postsynaptic density-95 protein;
- c) adding a test compound into said sample of free Postsynaptic density-95 protein to form a test sample;
- d) incubating said test compound with said PDZ domain to allow binding reaction;
- e) taking a second NMR spectrum of said incubated PDZ domain;
- f) making a comparison between ~~comparing~~ said first and second NMR spectra ~~wherein binding reaction is identified; and~~
- g) making an assessment about said test compound's potential as a neuroprotective drug based on said comparison in step(f).

Claim 2 (Currently amended): A method according to claim 1 wherein said PDZ domain has a second alpha-helix and a second beta-strand and said method further comprises the step of: ~~(g)~~ (h) identifying a test compound test samples that cause- that causes one or more chemical shift changes attributable to amino acid residues in the second .alpha.-helix and the second beta-strand ~~of PSD-95 PDZ2.~~

Claim 3 (Currently amended): A method according to claim 2 wherein said amino acid in step ~~(e)~~ (h) is at least one amino acid selected from the group consisting of glycine 169-alanine 175 in the second beta-strand and histidine 225 to lysine 233 the second .alpha.-helix ~~of PSD-95 PDZ2.~~

Claim 4 (Original): A method according to claim 1 wherein said test sample contains flavonoids.

Claim 5 (Original): A method according to claim 2 wherein said test sample contains flavonoids.

Claim 6 (Original): A method according to claim 3 wherein said test sample contains flavonoids.

Claim 7 (Original): A method according to claim 1 wherein said test sample contains a crude herbal extract.

Claim 8 (Original): A method according to claim 7 further comprising separating the components of said crude herbal extract; and repeating steps (a) to (d) to identify active ingredients therein.

Claim 9 (Original): A method according to claim 5 wherein said crude extract is an aqueous extract.

Claim 10 (Previously withdrawn): A method of treatment of brain damage in humans resulting from hypoxic or ischemic insults comprising administering an effective dose of baicalin, oroxylin A-glucuronide (oroxylside), wogonoside or nor-wogonoside.

Claim 11 (Previously withdrawn): A pharmaceutical composition comprising a substantially pure form of at least one flavanoid selected from a group comprising baicalin, oroxylin A-glucuronide (oroxylside), wogonoside and nor-wogonoside.

Claim 12 (Original): The method of claim 1, wherein said Post-synaptic density 95 protein comprises the sequence of SEQ ID NO: 2.

Claim 13 (Original): The method of claim 1, wherein said Post-synaptic density 95 protein comprises a polypeptide with at least 50% amino acid identity to the sequence of SEQ ID NO:2.

Claim 14 (Original): The method of claim 1, wherein said Post-synaptic density 95 protein comprises the sequence of SEQ ID NO: 6.

Claim 15 (Original): The method of claim 1, wherein said Post-synaptic density 95 protein comprises a polypeptide with at least 50% amino acid identity to the sequence of SEQ ID NO: 6.

Claim 16 (Original): The method of claim 1, wherein said Post-synaptic density 95 protein is encoded by a nucleic acid which hybridizes under stringent conditions to a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 5.

Claim 17 (Currently amended): A method of screening for compounds comprising the steps of  
obtaining a sample comprising the PDZ-2 domain of Post-synaptic density 95 protein;  
taking a first NMR spectrum of said PDZ-2 domain ~~of Post-synaptic density 95 protein;~~  
adding a test compound into said sample comprising ~~the PDZ~~ said PDZ-2 domain ~~of Post-synaptic density 95 protein~~ to form a test sample;  
incubating said test compound with said PDZ-2 domain to allow a binding reaction;  
taking a second NMR spectrum of said incubated PDZ-2 domain; ~~and~~  
comparing said first and second NMR spectra ~~wherein said binding reaction is identified;~~ and  
making an assessment about said test compound's potential as a neuroprotective drug.

Claim 18 (Currently amended): The method of claim 17, wherein said PDZ-2 domain comprises the sequence of SEQ ID NO: 4.

Claim 19 (Currently amended): The method of claim 17, wherein said PDZ-2 domain comprises a polypeptide with at least 50% amino acid identity to the sequence of SEQ ID NO: 4.

Claim 20 (Currently amended): The method of claim 17, wherein said PDZ-2 domain comprises the sequence of SEQ ID NO: 8.

Claim 21 (Currently amended): The method of claim 17, wherein said PDZ2 domain comprises a polypeptide with at least 50% amino acid identity to the sequence of SEQ ID NO: 8.

Claim 22 (Currently amended): The method of claim 17, wherein said PDZ2 domain is encoded by a nucleic acid which hybridizes under stringent conditions to a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 7.